Cambridge Cancer Genomics Company
Cambridge Cancer Genomics develops precision oncology solutions to transform the way cancer patients are treated. Using simple blood draws, CCG shortens the time required to know whether treatment is working, buying the clinician more time to alter treatment and reduce unnecessary side effects. The technology can detect relapse earlier than standard of care, predict response to therapy, and decrease ineffective treatment regimens. Over time, CCG will be able to better predict the best therapeutic strategy for cancer patients before they even begin treatment. Cambridge Cancer Genomics was founded on 2016 and is headquartered in Cambridge, England.
Investors
Connections from
Founded Date:
2016-01-01
Technology:
Medical BioTech
Funding Status:
M&A
Total Funding:
22035000
Employee Number:
11-50
Headquarters:
Cambridge, Cambridgeshire, United Kingdom
Last Funding Date:
2018-12-31
Investors Number:
10.0
Last Funding Type:
Seed
Estimated Revenue:
Less than $1M
Industry:
Medical BioTech